Focused On-demand Library for Myosin-7

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P12883

UPID:

MYH7_HUMAN

Alternative names:

Myosin heavy chain 7; Myosin heavy chain slow isoform; Myosin heavy chain, cardiac muscle beta isoform

Alternative UPACC:

P12883; A2TDB6; B6D424; Q14836; Q14837; Q14904; Q16579; Q2M1Y6; Q92679; Q9H1D5; Q9UDA2; Q9UMM8

Background:

Myosin-7, known alternatively as Myosin heavy chain 7, Myosin heavy chain slow isoform, and Myosin heavy chain, cardiac muscle beta isoform, plays a pivotal role in muscle contraction. It is an actin-based motor molecule with ATPase activity, essential for the contraction of skeletal and cardiac muscle by forming bipolar thick filaments.

Therapeutic significance:

Myosin-7 is implicated in several hereditary disorders, including familial hypertrophic cardiomyopathy, dilated cardiomyopathy, congenital myopathies, and left ventricular non-compaction. These conditions highlight the protein's critical role in cardiac and skeletal muscle function, suggesting that targeting Myosin-7 could lead to novel treatments for these debilitating diseases.